AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).
AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment.
AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver highly potent cancer-killing agents..